- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03612115
Neuromuscular Electrical Stimulation in Pulmonary Arterial Hypertension
August 1, 2018 updated by: Buse Ozcan Kahraman, Dokuz Eylul University
Investigation of the Effects of Neuromuscular Electrical Stimulation in Patients With Pulmonary Arterial Hypertension
This study aimed to investigate the effects of neuromuscular electrical stimulation on peripheral muscles and other physical and psychosocial variables in patients with pulmonary arterial hypertension.
This study was designed as an assessor-blind randomized controlled trial.
Thirty-one patients with pulmonary arterial hypertension will be recruited.
The participants will randomly divided two parallel groups as treatment and control.
For the treatment group, neuromuscular electrical stimulation will be applied to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.
Control group will not be received any additional treatment, just given healthy life recommendations such as walking.
The participants will be assessed before and after the treatment by a blind assessor to the group allocation.
The outcome measure will be assessments of the upper and lower limb muscle strength, respiratory muscle strength, muscle cross-sectional area and thickness, pulse wave velocity, exercise capacity, walking speed, functional mobility and balance performances, balance confidence, fatigue perceptions, physical activity level, activities of daily living and quality of life.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Izmir, Turkey, 35320
- Dokuz Eylul University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Elevated pulmonary artery pressures measured by right heart catheterization
- New York Heart Association class II or III
- Stabile Pulmonary Arterial Hypertension-specific pharmaceutical therapy for 3 months
Exclusion Criteria:
- Orthopaedic problems
- Significant restrictive or obstructive pulmonary disease
- Acute cor pulmonale.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Neuromuscular electrical stimulation intervention
Neuromuscular electrical stimulation treatment
|
Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks. Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France) |
NO_INTERVENTION: Control
No additional intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Isometric muscle strength
Time Frame: Change from Baseline at 8 weeks
|
Isometric muscle strength for knee extensors
|
Change from Baseline at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six-Minute Walk Test
Time Frame: Change from Baseline at 8 weeks
|
Change from Baseline at 8 weeks
|
|
Isometric muscle strength
Time Frame: Change from Baseline at 8 weeks
|
Isometric muscle strength for shoulder flexors and abductors
|
Change from Baseline at 8 weeks
|
Hand grip strength
Time Frame: Change from Baseline at 8 weeks
|
Hand grip strength
|
Change from Baseline at 8 weeks
|
Quadriceps femoris muscle thickness
Time Frame: Change from Baseline at 8 weeks
|
Change from Baseline at 8 weeks
|
|
Rectus femoris cross-sectional area
Time Frame: Change from Baseline at 8 weeks
|
Change from Baseline at 8 weeks
|
|
Pulse wave velocity
Time Frame: Change from Baseline at 8 weeks
|
Change from Baseline at 8 weeks
|
|
Six-Minute Pegboard and Ring Test
Time Frame: Change from Baseline at 8 weeks
|
Change from Baseline at 8 weeks
|
|
Sit-to-Stand Test
Time Frame: Change from Baseline at 8 weeks
|
Change from Baseline at 8 weeks
|
|
Timed-Up and Go Test
Time Frame: Change from Baseline at 8 weeks
|
Change from Baseline at 8 weeks
|
|
Activities-specific Balance Confidence Scale
Time Frame: Change from Baseline at 8 weeks
|
The Activities-specific Balance Confidence Scale is a 16-item instrument designed to measure a patient's perceived level of confidence in performing common activities of daily living without losing balance and falling.
The patient ranks his confidence to complete each item from 0% (no confidence) to 100% (complete confidence).
Total score is calculated as sum score ranged from 0 to 100.
Higher scores indicate higher balance confidence level.
|
Change from Baseline at 8 weeks
|
4-m Gait Speed Test
Time Frame: Change from Baseline at 8 weeks
|
Change from Baseline at 8 weeks
|
|
Fatigue Impact Scale
Time Frame: Change from Baseline at 8 weeks
|
The Fatigue Impact Scale is widely used to measure fatigue.
It is a 40-item multidimensional scale measuring the physical, cognitive and social.
Patients are asked to rate how much of a problem fatigue has caused them during the past month, including the day of testing, on a 5-point Likert-type scale, with response options ranging from 0 "no problem" to 4 "extreme problem".
Higher scores indicate the greater level of fatigue (total score ranged from 0 to 160).
|
Change from Baseline at 8 weeks
|
International Physical Activity Questionnaire-Short Form
Time Frame: Change from Baseline at 8 weeks
|
The International Physical Activity Questionnaire-Short Form has 7 items listing activities and requests estimates of durations and frequencies for each activity engaged in over the past week.
Durations are multiplied by known metabolic equivalents per activity and the results for all items are summed for the overall physical activity score.
Scores for walking and for moderate and vigorous activities are sums of corresponding item scores.
Higher scores indicate higher physical activity level.
|
Change from Baseline at 8 weeks
|
Milliken Activities of Daily Living Scale
Time Frame: Change from Baseline at 8 weeks
|
Milliken Activities of Daily Living Scale consists of 47 items including preparing meals, and eating (8 items), self-care (9 items), dressing oneself (8 items), manual manipulation of objects (9 items), house cleaning, and washing clothes (7 items), and other activities (6 items).
For scoring the level of ability to perform each item, a 5-point scale, and for the level of necessity to perform these items, a 3-point scale is used.
Total score can range from 0 to 705 points.
Higher scores indicate less limitation in activities of daily living.
|
Change from Baseline at 8 weeks
|
Nottingham Health Profile
Time Frame: Change from Baseline at 8 weeks
|
Health-related quality of life will be assessed using Nottingham Health Profile scale which is a general quality of life questionnaire that measures perceived health problems and their impact on normal daily activities.
It has 38 items divided into six domains: energy level, pain, emotional reactions, sleep, social isolation and physical abilities.
Items use yes/no answer format and each item is weighted.
Total scores for each domain range from 0 to 100.
Higher scores represent less quality of life in relevant domain.
|
Change from Baseline at 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 1, 2015
Primary Completion (ACTUAL)
September 28, 2017
Study Completion (ACTUAL)
September 28, 2017
Study Registration Dates
First Submitted
July 27, 2018
First Submitted That Met QC Criteria
July 27, 2018
First Posted (ACTUAL)
August 2, 2018
Study Record Updates
Last Update Posted (ACTUAL)
August 3, 2018
Last Update Submitted That Met QC Criteria
August 1, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2217-GOA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Neuromuscular electrical stimulation
-
Brooks RehabilitationTerminatedBlepharoptosis | LagophthalmosUnited States
-
University Hospital, BrestRecruitingAsthma | Chronic Obstructive Pulmonary Disease Overlap SyndromeFrance
-
Hacettepe UniversityNot yet recruiting
-
MetroHealth Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedStroke | Hemiparesis | FootdropUnited States
-
University of Sao PauloSuspendedRehabilitation | Critical CareBrazil
-
Research Institute for Complex Problems of Cardiovascular...UnknownHeart Failure | Sarcopenia | Peripheral Artery Disease | Exercise IntoleranceRussian Federation
-
Federal University of Rio Grande do SulEnrolling by invitation
-
University of Texas, El PasoRecruitingObesity | Overweight | Insulin ResistanceUnited States
-
University of PittsburghKing Fahad Specialist Hospital Dammam; Saudi Arabian Cultural MissionCompleted